Fragile Supply Chain Structure: Geographic Concentration & Limited Domestic Capacity in the United States

Girish Gupta
Director Supply Chain & Science Teacher Public High School VA, USA

* Corresponding Author: **Girish Gupta**

Article Info

ISSN (online): 3049-0421
Volume: 02
Issue: 02
March-April 2025
Received: 01-10-2025
Accepted: 02-11-2025
Page No: 54-59

Abstract
The United States faces critical vulnerabilities in its supply chain infrastructure, characterized by geographic concentration of manufacturing in select regions and limited domestic production capacity across multiple sectors. This research examines the structural fragilities that have emerged from decades of globalization, cost optimization, and just-in-time manufacturing practices. The analysis reveals that 72% of API facilities supplying the U.S. market are overseas, with significant dependencies on foreign production. An estimated 80% of APIs and 40% of finished pharmaceuticals consumed in the US are manufactured abroad, primarily in China and India. The study explores how economic efficiency priorities have inadvertently created systemic vulnerabilities that became evident during the COVID-19 pandemic and recent geopolitical tensions. Key findings demonstrate critical dependencies in pharmaceuticals, semiconductors, rare earth materials, and essential manufacturing. The research analyzes trade-offs between cost efficiency and supply chain resilience, examining how geographic concentration creates single points of failure across critical industries. Strategic recommendations include building domestic manufacturing capacity, supply chain diversification, and regional resilience frameworks while maintaining economic competitiveness in the global marketplace.

DOI: https://doi.org/10.54660/IJPGRR.2025.2.2.54-59

Keywords: Supply Chain Vulnerability, Geographic Concentration, Domestic Manufacturing, Resilience, Critical Dependencies, Reshoring, Strategic Industries, National Security

1. Introduction

The fragility of American supply chains has emerged as one of the most pressing economic and national security challenges of the 21st century [1]. The pursuit of cost optimization and economic efficiency through globalization has created a complex web of international dependencies that, while economically beneficial during stable periods, have proven vulnerable to disruption during crises[2]. The COVID-19 pandemic served as a stark reminder of how geographic concentration and limited domestic capacity can threaten critical supply chains, from essential medications to personal protective equipment [3].

The concept of supply chain fragility encompasses multiple dimensions of vulnerability, including geographic concentration of production facilities, supplier consolidation, inventory minimization, and transportation dependencies [4]. These structural characteristics, developed over decades of lean manufacturing practices and globalization strategies, have created efficiencies that come at the cost of resilience [5].

Geographic concentration refers to the clustering of manufacturing capabilities in specific regions or countries, often driven by factors such as labor costs, regulatory environments, infrastructure availability, and economies of scale [6]. This concentration creates systemic risks when disruptions affect entire geographic regions, as witnessed during the 2011 tsunami in Japan, the 2020 pandemic lockdowns in China, and recent geopolitical tensions affecting global trade [7].

Limited domestic capacity represents another critical vulnerability, where the United States has reduced or eliminated manufacturing capabilities for products deemed essential during crisis periods [8]. This reduction in domestic production capacity

has occurred across multiple sectors, from basic pharmaceuticals to advanced electronics, creating dependencies on foreign suppliers for critical materials and products [9].

2. Historical Development of Supply Chain Fragility

2.1. Evolution of Global Manufacturing Models

The development of fragile supply chain structures can be traced to the post-World War II era when American manufacturing dominated global production [10]. The subsequent decades witnessed a gradual shift toward international sourcing and offshore manufacturing driven primarily by cost arbitrage opportunities and comparative advantage principles [11].

The 1990s and 2000s marked an acceleration of supply chain globalization, with companies adopting just-in-time manufacturing, lean inventory models, and single-sourcing strategies to maximize efficiency and minimize costs [12]. These practices, while successful in reducing operational expenses and improving short-term profitability, systematically removed redundancy and buffer capacity from supply chains [13].

Trade liberalization and technological advances in communications and logistics enabled companies to coordinate complex global supply networks with unprecedented efficiency [14]. The WTO agreements, NAFTA, and bilateral trade deals facilitated the movement of production to low-cost countries, particularly in Asia [15].

2.2. The Rise of Asian Manufacturing Dominance

China's emergence as the "world's factory" fundamentally altered global supply chain geography, with many industries concentrating production in Chinese manufacturing hubs [16]. The Belt and Road Initiative further strengthened China's position as a global manufacturing center by improving infrastructure and trade connections [17].

India's pharmaceutical industry evolved to become a major supplier of generic drugs and active pharmaceutical ingredients, creating a duopoly with China that supplies the majority of the world's essential medicines [18]. This concentration was driven by regulatory arbitrage, cost advantages, and economies of scale that made Asian production significantly more cost-effective than domestic alternatives [19].

3. Geographic Concentration Vulnerabilities

3.1. Pharmaceutical Supply Chain Dependencies

The pharmaceutical industry shows the risks of geographic concentration. Over 80% of Active Pharmaceutical Ingredients (APIs) used in U.S. medications come from overseas. This concentration creates multiple layers of vulnerability across the pharmaceutical value chain. The COVID-19 pandemic highlighted these vulnerabilities. As global supply chains stopped, U.S. hospitals and pharmacies faced delays in getting essential medicines. This included everything from common antibiotics to critical drugs needed for ventilator treatments. Patients, already scared by the uncertainty of the virus, waited for medications that doctors could not always supply on time. Clinicians had to ration supplies, and families worried not only about the illness but also about whether life-saving medicines would be available when needed. One of the biggest shortages during this time was APAP (acetaminophen), a widely used pain reliever and fever reducer. It quickly became one of the most crucial medicines in the fight against COVID-19. APAP was vital for managing symptoms and saving millions of lives, often at a scale and speed not seen before. The surge in global demand clashed with the fragile supply chain, revealing the risks of depending heavily on overseas manufacturing. During this crisis, the pharmaceutical supply chain played a key role in connecting urgent demand with limited supply. Distribution networks, logistics providers, and manufacturers worked tirelessly, often under immense pressure, to redirect shipments, find alternative supplies, and speed up deliveries. Their ability to adjust and coordinate globally meant that, despite severe shortages, critical medicines like APAP could still reach the places they were needed most. The pandemic demonstrated that supply chains are more than just business operations—they are lifelines. Each successful delivery represented more than just filling shelves; it meant relief for a patient with a fever, support for overwhelmed hospitals, and often the difference between life and death. The shortages of APAP and other drugs highlighted the urgent need to create more resilient, diverse, and transparent pharmaceutical supply chains. This effort is crucial to protect public health and preserve human dignity during crises.

Generic Drug Manufacturing concentration in Asia has made these essential medications particularly vulnerable to supply disruptions [22]. Generic drugs, which represent over 90% of prescriptions filled in the United States, are predominantly manufactured in facilities located in India and China [23].

Specialty Manufacturing for complex biologics and advanced therapies also faces concentration risks, with many facilities located in specific geographic regions that may be vulnerable to natural disasters or geopolitical tensions [24].

3.2 Semiconductor Industry Concentration

The semiconductor industry represents another critical example of dangerous geographic concentration, with advanced chip manufacturing concentrated in Taiwan, South Korea, and China [25]. Taiwan Semiconductor Manufacturing Company (TSMC) alone produces over 60% of the world's semiconductors and over 90% of the most advanced chips [26]. This concentration creates systemic risks for industries dependent on advanced semiconductors, including automotive, telecommunications, defense, and consumer electronics [27]. The automotive industry has been particularly affected, with semiconductor shortages causing production shutdowns and delivery delays across major manufacturers [28].

3.3. Critical Materials and Rare Earth Elements

Rare earth element production is overwhelmingly concentrated in China, which controls approximately 80% of global production and processing capabilities [29]. These materials are essential for renewable energy technologies, defense systems, consumer electronics, and electric vehicle batteries [30].

4. Limited Domestic Manufacturing Capacity

4.1. Industrial Manufacturing Decline

The United States has experienced significant decline in domestic manufacturing capacity across multiple sectors over the past three decades. Heavy manufacturing capacity has been reduced in steel production, shipbuilding, machinery manufacturing, and chemical production.

Defense manufacturing capabilities have also been affected, with many defense contractors dependent on foreign suppliers for critical components and materials. This creates national security vulnerabilities and limits the ability to rapidly increase defense production when needed.

4.2 Pharmaceutical Manufacturing Erosion

Domestic pharmaceutical production has declined significantly, with API manufacturing virtually eliminated for many essential medications. Sterile injectable manufacturing represents a particular vulnerability, as these complex products require specialized facilities that have been consolidated globally.

The antibiotics manufacturing sector has been particularly affected, with the last major U.S. facility for producing key antibiotic ingredients closing in recent years.

5. Risk Assessment and Impact Analysis

5.1. Systemic Risk Identification

Critical node analysis reveals how certain manufacturing facilities, transportation hubs, and suppliers represent single points of failure for multiple industries. The Suez Canal blockage in 2021 demonstrated how transportation chokepoints can disrupt global supply chains.

Cascading failure risks occur when disruptions in one sector affect others, as seen in the semiconductor shortage's impact on automotive production and subsequent effects on steel demand.

5.2. Economic Impact Assessment

Supply chain disruptions create both direct and indirect economic costs, including production delays, inventory shortages, price increases, and opportunity costs. The **COVID-19 pandemic** resulted in estimated supply chain disruption costs exceeding $4 trillion globally.

6. Case Studies of Supply Chain Fragility

Case Study 1: COVID-19 PPE Crisis

The early COVID-19 pandemic revealed extreme vulnerabilities in Personal Protective Equipment (PPE) supply chains, with over 95% of N95 masks imported, primarily from China[42]. When Chinese production was redirected domestically and export restrictions implemented, U.S. healthcare systems faced critical shortages.

Case Study 2: Semiconductor Shortage Impact

The global semiconductor shortage beginning in 2020 demonstrated how geographic concentration and just-in-time manufacturing created vulnerabilities. The crisis particularly affected the automotive industry, where production shutdowns resulted in billions of dollars in lost revenue.

Case Study 3: Pharmaceutical Supply Disruptions

Hurricane Maria's impact on Puerto Rico in 2017 disrupted production of critical medications, including IV saline solutions, demonstrating how natural disasters can affect geographically concentrated manufacturing.

7. Strategic Response Framework

7.1. Reshoring and Nearshoring Initiatives

Manufacturing reshoring efforts have gained momentum, with companies bringing production back to the United States or relocating to nearby countries. Nearshoring to Mexico and Central America provides cost advantages while reducing geographic risk.

7.2. Supply Chain Diversification Strategies

Multi-sourcing strategies involve developing relationships with suppliers across different geographic regions to reduce concentration risk [29]. Regional supply networks create backup capabilities that can activate during primary source disruptions [30].

8. Comparative Analysis and Data Visualization

Table 1: Geographic Concentration Analysis by Critical Industry

Industry Sector	Primary Geographic Concentration	Domestic Capacity	Risk Level	Strategic Priority
Pharmaceuticals	China (40%), India (35%)	15% APIs, 25% Finished	Very High	Critical
Semiconductors	Taiwan (65%), South Korea (20%)	12% Advanced Chips	Extreme	Critical
Rare Earth Elements	China (80%), Myanmar (10%)	<2% Processing	Extreme	Critical
Solar Panels	China (75%), Southeast Asia (15%)	8% Manufacturing	High	Important
Medical Devices	Ireland (25%), Malaysia (20%)	45% Production	Moderate	Important
Steel Production	China (50%), Japan (6%)	65% Capacity	Moderate	Strategic
Chemical Manufacturing	China (35%), Germany (15%)	55% Production	Moderate	Important
Electronics Assembly	China (45%), Vietnam (15%)	20% Capacity	High	Important

Fig 1: Supply Chain Vulnerability Timeline (2000-2024)



Fig 2: Economic Impact of Supply Chain Disruptions



Fig 3: Supply Chain Resilience Framework

9. Policy Recommendations and Strategic Solutions

9.1. Government Intervention Strategies

Strategic stockpiling programs for critical materials and medications can provide buffer capacity during supply disruptions. The Strategic National Stockpile requires expansion and modernization to address current vulnerabilities.

Manufacturing incentives through tax credits, grants, and regulatory reforms can encourage domestic production of critical goods. The **CHIPS** Act represents a model for targeted industrial policy to rebuild domestic capacity.

9.2. Private Sector Resilience Building

Supply chain mapping and risk assessment programs enable companies to identify vulnerabilities and develop mitigation strategies. Collaborative partnerships between companies can share costs and risks of diversification efforts.

Technology investments in automation, artificial intelligence, and advanced manufacturing can help offset higher domestic labor costs and improve competitiveness.

10. Future Outlook and Implications

10.1. Emerging Trends and Challenges

Deglobalization trends may accelerate as companies prioritize resilience over efficiency. Regional trading blocs may emerge as alternatives to global supply chains.

Climate change impacts will create new vulnerabilities as extreme weather events become more frequent and severe. Cyber security threats to supply chain networks represent growing risks.

10.2. Technology Solutions and Innovations

Digital twins and AI-powered forecasting can improve supply chain visibility and risk prediction. Blockchain technology can enhance traceability and authentication across global networks.

Advanced manufacturing techniques including **3D** printing and modular production may enable more distributed and flexible manufacturing models.

11. Conclusion

The fragile structure of American supply chains, characterized by geographic concentration and limited domestic capacity, repressents a critical vulnerability that threatens economic security and national resilience. The COVID-19 pandemic and recent geopolitical tensions have demonstrated the real-world consequences of over-optimized supply chains that prioritize efficiency over security.

Addressing these vulnerabilities requires a comprehensive approach combining government policy, private sector investment, and international cooperation. The challenge lies in building resilience while maintaining the economic benefits of global trade and specialization.

The path forward involves strategic reshoring of critical capabilities, diversification of supply sources, and investment in domestic manufacturing capacity. Success will require sustained commitment and recognition that supply chain resilience is a strategic imperative that justifies some sacrifice of short-term efficiency for long-term security.

References

1. Simchi-Levi D, Simchi-Levi E. We need a stress test for critical supply chains. Harvard Business Review. 2020;98(4):90-98.
2. Christopher M, Peck H. Building the resilient supply chain. International Journal of Logistics Management. 2004;15(2):1-14.
3. Gereffi G. What does the COVID-19 pandemic teach us about global value chains? The case of medical supplies. Journal of International Business Policy. 2020;3(3):287-301.
4. Sheffi Y. The resilient enterprise: overcoming vulnerability for competitive advantage. Cambridge, MA: MIT Press; 2015.
5. Tang CS. Perspectives in supply chain risk management. International Journal of Production Economics. 2006;103(2):451-488.
6. Chopra S, Sodhi MS. Managing risk to avoid supply-chain breakdown. MIT Sloan Management Review. 2004;46(1):53-61.
7. Park K, Min H, Min S. Inter-relationship among risk taking propensity, supply chain security practices, and supply chain disruption occurrence. Journal of Purchasing and Supply Management. 2016;22(2):120-130.
8. Helper S. Rebuilding manufacturing: post-COVID-19 supply chain solutions. Washington, DC: Brookings Institution; 2020.
9. Fuchs ER, Kirchain RE. Design for location? The impact of manufacturing offshore on technology competitiveness in the optoelectronics industry. Management Science. 2010;56(12):2323-2349.
10. Baldwin R. The great convergence: information technology and the new globalization. Cambridge, MA: Harvard University Press; 2016.
11. Antràs P. De-globalisation? Global value chains in the post-COVID-19 age. NBER Working Paper No. 28115. Cambridge, MA: National Bureau of Economic Research; 2020.
12. Womack JP, Jones DT, Roos D. The machine that changed the world: the story of lean production. New York: Free Press; 2007.
13. Harrison A, McMillan M. Offshoring jobs? Multinationals and U.S. manufacturing employment. Review of Economics and Statistics. 2011;93(3):857-875.
14. Feenstra RC, Hanson GH. Globalization, outsourcing, and wage inequality. American Economic Review. 1996;86(2):240-245.
15. Rodrik D. What do trade agreements really do? Journal of Economic Perspectives. 2018;32(2):73-90.
16. Naughton B. The Chinese economy: transitions and growth. Cambridge, MA: MIT Press; 2007.
17. Huang Y. Understanding China's Belt & Road Initiative. Vancouver: Asia Pacific Foundation of Canada; 2016.
18. Chaudhuri S. The WTO and India's pharmaceuticals industry: patent protection, TRIPS, and developing countries. New Delhi: Oxford University Press; 2005.
19. Kumar N, Pradhan JP. Foreign direct investment, externalities and economic growth in developing countries. Basingstoke: Palgrave Macmillan; 2005.
20. U.S. Food and Drug Administration. Drug shortages: root causes and potential solutions. Silver Spring, MD: FDA; 2019.
21. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clinical Pharmacology & Therapeutics. 2013;93(2):170-176.

22. Blackstone EA, Fuhr JP Jr, Pociask S. The health and economic effects of counterfeit drugs. American Health & Drug Benefits. 2014;7(4):216-224.
23. Association for Accessible Medicines. Generic drug access and savings in the US: 2020 report. Washington, DC: AAM Foundation; 2020.
24. IQVIA Institute. The use of medicines in the U.S. 2020: usage and spending trends and outlook to 2024. Parsippany, NJ: IQVIA; 2020.
25. Semiconductor Industry Association. Taking stock: Taiwan's dominance of the semiconductor manufacturing market and its implications for U.S. industrial strength and economic security. Washington, DC: SIA; 2021.
26. Miller C. Chip war: the fight for the world's most critical technology. New York: Scribner; 2022.
27. McKinsey Global Institute. The semiconductor decade: a trillion-dollar industry. New York: McKinsey & Company; 2021.
28. Deloitte. Semiconductor shortage: how the automotive industry can navigate supply chain disruptions. Deloitte Insights. 2021.
29. U.S. Geological Survey. Mineral commodity summaries 2021: rare earths. Reston, VA: USGS; 2021.
30. Congressional Research Service. Rare earth elements in national defense: background, oversight issues, and options for Congress. Washington, DC: CRS; 2021. Report No. R41744.